peptides for FAQ

Skip peptide protocols entirely and consult an endocrinologist. Low cortisol at all timepoints (<5 ng/mL waking, <1 ng/mL throughout the day) suggests primary adrenal insufficiency or secondary insufficiency from pituitary dysfunction. Neither responds to peptides that work by modulating existing cortisol output. True adrenal insufficiency requires hydrocortisone replacement, not HPA axis modulators.

Cerebrolysin's peptide fractions degrade in the gastrointestinal tract, which is why every clinical trial uses intravenous infusion. Oral cerebrolysin would be enzymatically cleaved into constituent amino acids before reaching systemic circulation—eliminating the intact peptide sequences responsible for neurotrophic receptor binding. No oral formulation has demonstrated bioequivalence to IV cerebrolysin in pharmacokinetic studies.

Absence of subjective improvement doesn't confirm failure. Subtle changes in synaptic density or BDNF expression may precede measurable cognitive gains. Rodent studies show neurogenesis effects peak at 4–8 weeks but behavioural changes lag by an additional 2–4 weeks. If objective testing shows no improvement at 12 weeks, reassess protocol variables: dosage accuracy, reconstitution technique, injection timing relative to circadian BDNF fluctuations (which peak in early morning). If all variables are controlled and testing remains flat, the compound may not be effective for your neurobiology. Peptide response is individual.

Reduce dosing frequency or switch to evening-only administration. Healthy cortisol rhythm requires a robust morning peak. The cortisol awakening response (CAR) should be 50–75% above baseline within 30 minutes of waking. If morning cortisol falls below 10nmol/L (measured via saliva 30 minutes post-waking), you've overcorrected. Selank and Semax don't cause primary adrenal insufficiency, but excessive GABAergic tone can blunt the normal circadian surge. Dose Selank only in the afternoon and evening to preserve the morning CAR while still reducing evening cortisol.

Reduce the HCG dose first. Estradiol elevation on HCG is dose-dependent. Intratesticular testosterone is aromatised locally, and HCG doses above 500 IU per injection drive excessive conversion. Drop to 250 IU every other day and retest estradiol in four weeks. If estradiol remains >50 pg/mL after dose reduction, a low-dose aromatase inhibitor (0.25–0.5mg anastrozole twice weekly) can be added, but our experience shows most cases resolve with HCG dose adjustment alone. Over-suppressing estradiol (<20 pg/mL) negatively affects lipid profiles, bone density, and mood. Aromatase inhibitors should be the last adjustment, not the first.

Peptides targeting immune pathways don't interact pharmacokinetically with serotonin-norepinephrine reuptake inhibitors (duloxetine) or calcium channel modulators (pregabalin) because they operate through separate mechanisms. Combining peptide therapy with conventional fibromyalgia medications is common in investigational protocols. The peptides address upstream immune dysregulation while pharmaceuticals modulate neurotransmitter signaling and central pain processing. Monitor for additive effects (greater symptom reduction than either intervention alone) and work with your prescribing physician to adjust pharmaceutical dosing if peptide efficacy allows tapering.

Discard it immediately. Lyophilised peptides should reconstitute into a clear, colourless solution. Cloudiness indicates protein aggregation or contamination—both render the compound biologically inactive and potentially immunogenic. This most commonly occurs when bacteriostatic water is stored improperly or when the lyophilised powder was exposed to humidity before reconstitution. Never inject cloudy peptide solutions—the risk of injection site reaction or systemic immune response outweighs any potential benefit.

Combining peptides with different mechanisms (anti-inflammatory + synaptogenic) is mechanistically sound and supported by preclinical data showing additive effects. Thymalin + Cerebrolysin, or P21 + Dihexa, target complementary pathways. One prevents loss while the other supports growth. Avoid combining peptides with overlapping mechanisms (e.g., two synaptogenic compounds) unless dose-limiting side effects prevent reaching therapeutic levels with a single agent. More isn't always better; receptor saturation plateaus exist.

Check the cycle day of administration—kisspeptin only triggers ovulation when a dominant follicle is already present (typically cycle day 12–14 in a 28-day cycle). Administering it during the early follicular phase (days 3–8) won't work because no mature follicle exists to respond to the LH surge. Ultrasound monitoring to confirm follicle size (≥18mm) before injection is essential. If follicle development is absent despite FSH priming, the issue is ovarian response—not hypothalamic signalling—and peptide therapy won't resolve it.

No peptide has been studied in primary prevention—meaning cognitively healthy individuals using peptides to reduce future dementia risk. All cerebrolysin trials enrolled patients with diagnosed Alzheimer's or vascular dementia; no trial has followed healthy adults for decades to measure incident dementia rates. Using investigational peptides preventively means accepting zero evidence of benefit and unknown long-term safety profiles.

You'll wait indefinitely unless a research institution or pharmaceutical company sponsors formal trials. Dihexa synthesis is straightforward, but moving from rodent efficacy to Phase I human trials requires regulatory approval, institutional review board oversight, and funding—none of which currently exists for this compound. Using dihexa now means participating in uncontrolled self-experimentation with unknown risks.

Switch to combination protocols or investigate non-HPA drivers. If salivary cortisol AUC hasn't decreased by at least 15% after 28 days of consistent Selank dosing, the dysregulation may involve impaired glucocorticoid receptor function rather than excessive CRH secretion. Adding Semax to restore hippocampal receptor sensitivity can address this. The two peptides act at different points in the feedback loop. Alternatively, check inflammatory markers (CRP, IL-6). If chronically elevated, thymosin peptides may be necessary to remove cytokine-driven HPA activation.

No. Discard it immediately. Cloudiness indicates bacterial contamination or protein aggregation from improper storage or reconstitution technique. Lyophilised peptides are sterile until mixed with bacteriostatic water; introducing air bubbles during reconstitution, using non-sterile water, or exposing the vial to temperatures above 8°C post-mixing causes irreversible protein denaturation. A properly reconstituted peptide solution is clear and colourless. Any opacity, particulates, or discolouration means the amino-acid structure has degraded and the peptide is pharmacologically inactive.

Expect this. It's a documented rebound effect. When CRH signaling is chronically elevated, the hypothalamus has downregulated its own feedback receptors. Introducing T-reg cytokines that lower CRH initially disinhibits those receptors, causing a brief 5–7 day period where cortisol may spike 10–15% above baseline before dropping. This resolves without intervention and doesn't indicate protocol failure.

Elevated fasting glucose (>100 mg/dL) or rising HbA1c during MK-677 use signals developing insulin resistance. A known risk with chronic growth hormone elevation. Reduce dosing frequency immediately to 5-on/2-off cycling, or discontinue if glucose remains elevated after adjustment. MK-677's metabolic effects are dose-dependent; some users tolerate 12.5mg daily while others see glucose dysregulation at 25mg. Monitor fasting glucose weekly during any growth hormone secretagogue protocol.

Continue the protocol through at least 12 weeks before reassessing. Thymic reconstitution requires 8–12 weeks for CD4+ T-cell maturation from naive precursors to functional effector cells. Thymopoiesis isn't an acute process. Clinical trials showing Thymalin efficacy measured outcomes at 12-week endpoints, not 4-week. The exception is MK-677: if IGF-1 levels don't increase by week 4 (verifiable through serum testing), either absorption is impaired or the ghrelin receptor pathway isn't the limiting factor in your specific case.

Yes, but timing matters. Progesterone supplementation typically begins 1–3 days post-ovulation to support luteal phase endometrial thickening. Follistatin should be administered starting on cycle day 21 (mid-luteal phase) to coincide with the implantation window. The two don't interact pharmacologically, but both require subcutaneous or intramuscular injection—patients should rotate injection sites to prevent lipohypertrophy. Combining them into a single syringe is not recommended unless both are formulated in identical carrier solutions.

Administer the missed dose as soon as you remember if fewer than 48 hours have passed. If more than 48 hours have elapsed, skip the missed dose and resume your regular schedule. Tβ4's mechanism (Treg upregulation) builds cumulatively over weeks—missing a single dose doesn't erase prior progress, but missing multiple doses reduces therapeutic plasma levels below the threshold needed to suppress uNK cell activity. Consistency matters more than perfection.

Administer zinc picolinate (30mg daily) for two weeks before initiating Thymalin. Thymulin. The peptide hormone Thymalin helps restore. Requires zinc as a structural cofactor for receptor binding. Patients with serum zinc below 80 mcg/dL show blunted T-regulatory cell response and minimal IL-6 reduction even at standard Thymalin doses. The two-week saturation window allows hepatic zinc stores to normalize before introducing the thymic peptide.

Start with immune reconstitution first. Thymalin's restoration of regulatory T-cells (Tregs) reduces systemic inflammation that drives secondary neuroinflammation. A 2021 study in autoimmune encephalitis patients showed that Treg restoration via thymic peptides reduced CNS inflammation markers by 38%. Without direct CNS-targeted therapy. Complete one full Thymalin cycle (3 months, 3 pulse rounds) before adding Cerebrolysin or P21. Stacking immune and neurotrophic peptides simultaneously makes it impossible to isolate which mechanism drove improvement or adverse effects.